A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis

BMC Microbiology

Volumn 11, Issue , 2011, Pages

  Santiso, Rebeca ^a,b   Tamayo, María ^a,b   Gosálvez, Jaime ^c   Bou, Germán ^d   Fernández, María Del Carmen ^d   Fernández, José ^a,b  

^a Unidad de Genética   (Spain)

^b Laboratorio de Genética Molecular y Radiobiología   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Servicio de Microbiologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BACTERIAL DNA; BETA LACTAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; DEOXYRIBONUCLEASE I; IMIPENEM; PEPTIDOGLYCAN; PROTEINASE K; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BIOSYNTHESIS; CONTROLLED STUDY; DNA FRAGMENTATION; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; BACTERIAL INFECTION; BACTERIUM; DOWN REGULATION; DRUG EFFECT; EVALUATION; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DOWN-REGULATION; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDOGLYCAN;

EID: 80052028415     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-11-191     Document Type: Article

References (21)

1. Bacterial wall as target for attack: past, present, and future research. Koch AL, Clin Microbiol Rev 2003 16 4 673 687 10.1128/CMR.16.4.673-687.2003 14557293 (Pubitemid 37296555)
2. Bacterial cell wall synthesis: new insights from localization studies. Scheffers D-J, Pinto MG, Microbiol Mol Biol Rev 2005 69 4 585 607 10.1128/MMBR.69.4.585-607.2005 16339737 (Pubitemid 41798464)
3. Molecular control of bacterial death and lysis. Rice KC, Bayles KW, Microbiol Mol Biol Rev 2008 72 1 85 109 10.1128/MMBR.00030-07 18322035 (Pubitemid 351398056)
4. Discovery and development of new antimicrobial agents. Gootz TD, Clin Microbiol Rev 1990 3 1 13 31 2404566 (Pubitemid 20078772)
5. Triggering of autolytic cell wall degradation in Escherichia coli by beta-lactam antibiotics. Kitano K, Tomasz A, Antimicrob Agents Chemother 1979 16 6 838 848 93877 (Pubitemid 10082045)
6. Beta-lactam antibiotic resistance: a current structural perspective. Wilke MS, Lovering AL, Strynadka NC, Curr Opin Microbiol 2005 8 5 525 533 10.1016/j.mib.2005.08.016 16129657 (Pubitemid 41355032)
7. Updated functional classification of -lactamases. Bush K, Jacoby GA, Antimicrob Agents Chemother 2010 54 3 969 976 10.1128/AAC.01009-09 19995920
8. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Bradford PA, Clin Microbiol Rev 2001 14 4 933 951 10.1128/CMR.14.4.933-951.2001 11585791 (Pubitemid 32979636)
9. Glycopeptide and lipoglycopeptide antibiotics. Kahne D, Leimkuhler C, Lu W, Walsh C, Chem Rev 2005 105 2 425 448 10.1021/cr030103a 15700951 (Pubitemid 40356089)
10. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML, Clin Microbiol Rev 2010 23 1 99 139 10.1128/CMR.00042-09 20065327
11. Vancomycin-resistance transferability from VanA Enterococci to Staphylococcus aureus. de Niederhäusen S, Bondi M, Messi P, Issepi R, Sabia C, Manicardi G, Anacarso I, Curr Microbiol 2011 62 5 1363 1367 10.1007/s00284-011-9868-6 21234755
12. Hospital acquired infections due to gram-negative bacteria. Peleg AY, Hooper DC, N Engl J Med 2010 362 19 1804 1813 10.1056/NEJMra0904124 20463340
13. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Fraimow HS, Tsigrelis C, Crit Care Clin 2011 27 1 163 205 10.1016/j.ccc.2010.11.002 21144992
14. DNA fragmentation in microorganisms assessed in situ. Fernández JL, Cartelle M, Muriel L, Santiso R, Tamayo M, Goyanes V, Gosálvez J, Bou G, Appl Environ Microbiol 2008 74 19 5925 5933 10.1128/AEM.00318-08 18689511
15. Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from Escherichia coli using an in situ DNA fragmentation assay. Tamayo M, Santiso R, Gosálvez J, Bou G, Fernández JL, BMC Microbiol 2009 9 69 10.1186/1471-2180-9-69 19364397
16. Rapid and simple determination of ciprofloxacin resistance in clinical strains of Escherichia coli. Santiso R, Tamayo M, Fernández JL, Fernández MC, Molina F, Gosálvez J, Bou G, J Clin Microbiol 2009 47 8 2593 2595 10.1128/JCM.00367-09 19571026
17. The cell wall of Escherichia coli: early effects of penicillin treatment and deprivation of diaminopimelic acid. Bayer ME, J Gen Microbiol 1967 46 2 237 246 5339792
18. A common mechanism of cellular death induced by bactericidal antibiotics. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ, Cell 2007 130 5 797 810 10.1016/j.cell.2007.06.049 17803904 (Pubitemid 47332566)
19. Quinolone-mediated bacterial death. Drlica K, Malik M, Kerns RJ, Zhao X, Antimicrob Agents Chemother 2008 52 2 385 392 10.1128/AAC.01617-06 17724149 (Pubitemid 351170804)
20. An electron microscopic study of antagonism between cephalexin and erythromycin in Staphylococcus aureus. Nishino T, Jpn J Microbiol 1975 19 1 53 63 1160202
21. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. Katayama Y, Zhang H-Z, Chambers HF, Microb Drug Resist 2003 9 4 329 336 10.1089/107662903322762752 15000739 (Pubitemid 38168188)